175 related articles for article (PubMed ID: 34913076)
21. MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation.
Lee KM; Giltnane JM; Balko JM; Schwarz LJ; Guerrero-Zotano AL; Hutchinson KE; Nixon MJ; Estrada MV; Sánchez V; Sanders ME; Lee T; Gómez H; Lluch A; Pérez-Fidalgo JA; Wolf MM; Andrejeva G; Rathmell JC; Fesik SW; Arteaga CL
Cell Metab; 2017 Oct; 26(4):633-647.e7. PubMed ID: 28978427
[TBL] [Abstract][Full Text] [Related]
22. Myeloid Cell Leukemia 1 Small Molecule Inhibitor S63845 Synergizes with Cisplatin in Triple-Negative Breast Cancer.
Acton A; Placzek WJ
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760451
[TBL] [Abstract][Full Text] [Related]
23. Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems.
Shang E; Zhang Y; Shu C; Ishida CT; Bianchetti E; Westhoff MA; Karpel-Massler G; Siegelin MD
Sci Rep; 2018 Oct; 8(1):15383. PubMed ID: 30337641
[TBL] [Abstract][Full Text] [Related]
24. Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists.
Lestini BJ; Goldsmith KC; Fluchel MN; Liu X; Chen NL; Goyal B; Pawel BR; Hogarty MD
Cancer Biol Ther; 2009 Aug; 8(16):1587-95. PubMed ID: 19556859
[TBL] [Abstract][Full Text] [Related]
25. In vitro activity of a G-quadruplex-stabilizing small molecule that synergizes with Navitoclax to induce cytotoxicity in acute myeloid leukemia cells.
Montoya JJ; Turnidge MA; Wai DH; Patel AR; Lee DW; Gokhale V; Hurley LH; Arceci RJ; Wetmore C; Azorsa DO
BMC Cancer; 2019 Dec; 19(1):1251. PubMed ID: 31881855
[TBL] [Abstract][Full Text] [Related]
26. Involvement of MCL1, c-myc, and cyclin D2 protein degradation in ponatinib-induced cytotoxicity against T315I(+) Ph+leukemia cells.
Inoue C; Sobue S; Kawamoto Y; Nishizawa Y; Ichihara M; Abe A; Hayakawa F; Suzuki M; Nozawa Y; Murate T
Biochem Biophys Res Commun; 2020 May; 525(4):1074-1080. PubMed ID: 32184020
[TBL] [Abstract][Full Text] [Related]
27. MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-X
Yasuda Y; Ozasa H; Kim YH; Yamazoe M; Ajimizu H; Yamamoto Funazo T; Nomizo T; Tsuji T; Yoshida H; Sakamori Y; Nakajima N; Menju T; Yoshizawa A; Date H; Hirai T
Cell Death Dis; 2020 Mar; 11(3):177. PubMed ID: 32152266
[TBL] [Abstract][Full Text] [Related]
28. SH003 selectively induces p73‑dependent apoptosis in triple‑negative breast cancer cells.
Choi EK; Kim SM; Hong SW; Moon JH; Shin JS; Kim JH; Hwang IY; Jung SA; Lee DH; Lee EY; Lee S; Kim H; Kim D; Kim YS; Choi YK; Kim HI; Choi HS; Cho SG; Kim JE; Kim KP; Hong YS; Lee WK; Lee JS; Kim TW; Ko SG; Jin DH
Mol Med Rep; 2016 Oct; 14(4):3955-60. PubMed ID: 27599791
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of MARCH5 ubiquitin ligase abrogates MCL1-dependent resistance to BH3 mimetics via NOXA.
Subramanian A; Andronache A; Li YC; Wade M
Oncotarget; 2016 Mar; 7(13):15986-6002. PubMed ID: 26910119
[TBL] [Abstract][Full Text] [Related]
30. Antitumor effects of Xi Huang pills on MDA‑MB‑231 cells in vitro and in vivo.
Zheng W; Han S; Jiang S; He X; Li X; Ding H; Cao M; Li P
Mol Med Rep; 2018 Aug; 18(2):2068-2078. PubMed ID: 29956784
[TBL] [Abstract][Full Text] [Related]
31. DNA-PKcs, a novel functional target of acriflavine, mediates acriflavine's p53-dependent synergistic anti-tumor efficiency with melphalan.
Cao J; Lin G; Gong Y; Pan P; Ma Y; Huang P; Ying M; Hou T; He Q; Yang B
Cancer Lett; 2016 Dec; 383(1):115-124. PubMed ID: 27693638
[TBL] [Abstract][Full Text] [Related]
32. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.
Roberts AW; Seymour JF; Brown JR; Wierda WG; Kipps TJ; Khaw SL; Carney DA; He SZ; Huang DC; Xiong H; Cui Y; Busman TA; McKeegan EM; Krivoshik AP; Enschede SH; Humerickhouse R
J Clin Oncol; 2012 Feb; 30(5):488-96. PubMed ID: 22184378
[TBL] [Abstract][Full Text] [Related]
33. MUC1 Aptamer-Capped Mesoporous Silica Nanoparticles for Navitoclax Resistance Overcoming in Triple-Negative Breast Cancer.
Vivo-Llorca G; Candela-Noguera V; Alfonso M; García-Fernández A; Orzáez M; Sancenón F; Martínez-Máñez R
Chemistry; 2020 Dec; 26(69):16318-16327. PubMed ID: 32735063
[TBL] [Abstract][Full Text] [Related]
34. Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis.
Arai S; Jonas O; Whitman MA; Corey E; Balk SP; Chen S
Clin Cancer Res; 2018 Nov; 24(21):5458-5470. PubMed ID: 30021909
[No Abstract] [Full Text] [Related]
35. Transcript-level regulation of MALAT1-mediated cell cycle and apoptosis genes using dual MEK/Aurora kinase inhibitor "BI-847325" on anaplastic thyroid carcinoma.
Samimi H; Haghpanah V; Irani S; Arefian E; Sohi AN; Fallah P; Soleimani M
Daru; 2019 Jun; 27(1):1-7. PubMed ID: 31077090
[TBL] [Abstract][Full Text] [Related]
36. 17‑AAG synergizes with Belinostat to exhibit a negative effect on the proliferation and invasion of MDA‑MB‑231 breast cancer cells.
Zuo Y; Xu H; Chen Z; Xiong F; Zhang B; Chen K; Jiang H; Luo C; Zhang H
Oncol Rep; 2020 Jun; 43(6):1928-1944. PubMed ID: 32236631
[TBL] [Abstract][Full Text] [Related]
37. Confounding off-target effects of BH3 mimetics at commonly used concentrations: MIM1, UMI-77, and A-1210477.
Mallick DJ; Soderquist RS; Bates D; Eastman A
Cell Death Dis; 2019 Feb; 10(3):185. PubMed ID: 30796196
[TBL] [Abstract][Full Text] [Related]
38. ABT-263-induced MCL1 upregulation depends on autophagy-mediated 4EBP1 downregulation in human leukemia cells.
Lee YC; Wang LJ; Huang CH; Shi YJ; Chang LS
Cancer Lett; 2018 Sep; 432():191-204. PubMed ID: 29913235
[TBL] [Abstract][Full Text] [Related]
39. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).
Leverson JD; Zhang H; Chen J; Tahir SK; Phillips DC; Xue J; Nimmer P; Jin S; Smith M; Xiao Y; Kovar P; Tanaka A; Bruncko M; Sheppard GS; Wang L; Gierke S; Kategaya L; Anderson DJ; Wong C; Eastham-Anderson J; Ludlam MJ; Sampath D; Fairbrother WJ; Wertz I; Rosenberg SH; Tse C; Elmore SW; Souers AJ
Cell Death Dis; 2015 Jan; 6(1):e1590. PubMed ID: 25590800
[TBL] [Abstract][Full Text] [Related]
40. Regulation of HPV16 E6 and MCL1 by SF3B1 inhibitor in head and neck cancer cells.
Gao Y; Trivedi S; Ferris RL; Koide K
Sci Rep; 2014 Aug; 4():6098. PubMed ID: 25139387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
